Three HCV Drug Candidates Proceed to Phase II
Share
Follow Us
The Editors at Hepatitis Central
March 5, 2010
Hepatitis C drug candidates ABT-450, ABT-333 and ABT-072 move into Phase II testing.
Abbott, Enanta moving Hepatitis C drug development
March 2, 2010
NEW YORK
Abbott Laboratories and partner Enanta Pharmaceuticals on Tuesday said they will move potential hepatitis C treatments into midstage development.
The companies said they will evaluate three potential hepatitis C drugs in Phase 2 clinical trials.
Continue reading this entire article:
http://www.businessweek.com/ap/financialnews/D9E6J6M81.htm
